UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
On April 13, UBS analyst Michael Yee lifted the firm's price recommendation on Merck & Co., Inc. (NYSE:MRK) to $145 from $130. It reiterated a Buy rating on the shares. The revision was part of a broader Q1 preview across the pharmaceuticals and biotechnology group. A few days earlier, on April 7, the company said it would begin a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Terns Pharmaceuticals. This followed an earlier move on March 25, 2026, when Merck entered into a definitive agreement to acquire Terns. If the offer closes as expected, Terns stockholders will receive $53.00 net in cash for each share that is validly tendered and not withdrawn. The payment will not include interest and will be subject to any applicable tax withholding. After the shares are purchased through the tender offer, Terns will become a wholly owned subsidiary of Merck. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on delivering
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Roche's DAC investment; Big Pharma's lavish CEO bumps [Yahoo! Finance]Yahoo! Finance
- Better Pharma Dividend Stock: Novartis vs. Merck [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Better Pharma Dividend Stock: Novartis vs. Merck [Yahoo! Finance]Yahoo! Finance
- European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonBusiness Wire
- Harbour BioMed Appoints Dr. Adam Zong as President [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- 4/8/26 - Form DEF
- MRK's page on the SEC website